FORMA THERAPEUTICS HOLDINGS (FMTX) Stock Price, Quote, News and Overview
NASDAQ:FMTX - Nasdaq - US34633R1041 - Common Stock - Currency: USD
FMTX Quote, Performance and Key Statistics
20.01
+0.03 (+0.15%)
The current stock price of FMTX is 20.01 USD. In the past month the price increased by 0.2%. In the past year, price increased by 10.61%.
FMTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About FMTX
Company Profile
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 189 full-time employees. The company went IPO on 2020-06-16. The firm is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.
Company Info
FORMA THERAPEUTICS HOLDINGS
300 North Beacon Street, Suite 501
Watertown MASSACHUSETTS 02472 US
CEO: Frank D. Lee
Employees: 189
Company Website: https://ir.formatherapeutics.com/
Phone: 16176791970.0
FORMA THERAPEUTICS HOLDINGS / FMTX FAQ
What is the stock price of FORMA THERAPEUTICS HOLDINGS today?
The current stock price of FMTX is 20.01 USD. The price increased by 0.15% in the last trading session.
What is the ticker symbol for FORMA THERAPEUTICS HOLDINGS stock?
The exchange symbol of FORMA THERAPEUTICS HOLDINGS is FMTX and it is listed on the Nasdaq exchange.
On which exchange is FMTX stock listed?
FMTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FORMA THERAPEUTICS HOLDINGS stock?
12 analysts have analysed FMTX and the average price target is 21.01 USD. This implies a price increase of 5.01% is expected in the next year compared to the current price of 20.01. Check the FORMA THERAPEUTICS HOLDINGS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FORMA THERAPEUTICS HOLDINGS worth?
FORMA THERAPEUTICS HOLDINGS (FMTX) has a market capitalization of 957.53M USD. This makes FMTX a Small Cap stock.
How many employees does FORMA THERAPEUTICS HOLDINGS have?
FORMA THERAPEUTICS HOLDINGS (FMTX) currently has 189 employees.
What are the support and resistance levels for FORMA THERAPEUTICS HOLDINGS (FMTX) stock?
FORMA THERAPEUTICS HOLDINGS (FMTX) has a support level at 19.97 and a resistance level at 20.02. Check the full technical report for a detailed analysis of FMTX support and resistance levels.
Should I buy FORMA THERAPEUTICS HOLDINGS (FMTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FMTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FMTX, evaluating the profitability, health, valuation and growth aspects
- FORMA THERAPEUTICS HOLDINGS (FMTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FORMA THERAPEUTICS HOLDINGS (FMTX) Sales and EPS estimates to see what analysts future expectations are.
- FORMA THERAPEUTICS HOLDINGS (FMTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FORMA THERAPEUTICS HOLDINGS (FMTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- FORMA THERAPEUTICS HOLDINGS (FMTX) Stock Chart to make your own analysis
- FORMA THERAPEUTICS HOLDINGS (FMTX) Latest news and press-releases to stay up to date.
Does FORMA THERAPEUTICS HOLDINGS (FMTX) stock pay dividends?
FMTX does not pay a dividend.
When does FORMA THERAPEUTICS HOLDINGS (FMTX) report earnings?
FORMA THERAPEUTICS HOLDINGS (FMTX) will report earnings on 2022-11-11, before the market open.
What is the Price/Earnings (PE) ratio of FORMA THERAPEUTICS HOLDINGS (FMTX)?
FORMA THERAPEUTICS HOLDINGS (FMTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4).
FMTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FMTX. When comparing the yearly performance of all stocks, FMTX is one of the better performing stocks in the market, outperforming 99.11% of all stocks.
FMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FMTX. FMTX has a great financial health rating, but its profitability evaluates not so good.
FMTX Financial Highlights
Over the last trailing twelve months FMTX reported a non-GAAP Earnings per Share(EPS) of -4. The EPS decreased by -32.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.02% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
FMTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to FMTX. The Buy consensus is the average rating of analysts ratings from 12 analysts.